Deals · BioTech

Cellbox Solutions completes €5M Series A to scale warm-chain logistics for living cells

A Cologne-based biotech logistics company providing portable CO₂ incubator systems — Cellbox Go Ground, Cellbox Go Flight, and Cellbox Shipper — that maintain controlled temperature and atmosphere for live biological materials in transit.

ProYarn Desk · October 20, 2026Read this in French

in 𝕏 ✆

“Over the past years, we have built a strong foundation for the controlled transport of living biological materials. This financing lets us accelerate that work and bring our warm-chain infrastructure to the organisations that need it most.”

Prof. Dr. Kathrin Adlkofer — CEO, Cellbox Solutions

Cellbox Solutions (Cologne) has completed a €5M Series A, bringing in Baltic Business Angels Invest GmbH as a new investor alongside existing backers NRW.BANK and Fraunhofer Venture. The round represents the final close of the Series A; a first tranche of €3.5M was raised in March 2026. The company was co-founded by Prof. Dr. Kathrin Adlkofer (CEO) and Dr. Bernd Muehlenweg (CBO/CFO) and has built portable CO₂ incubator systems for the transport of live biological materials since 2017.

What Cellbox builds

The core product family comprises three systems. Cellbox Go Ground is designed for same-day and overnight road and rail shipments. Cellbox Go Flight handles air freight with aviation-certified pressurisation. Cellbox Shipper is a compact, portable unit for courier delivery of small-volume samples. All three maintain the CO₂ concentration, temperature, and humidity required to keep primary cells, tissue samples, and cell therapy products viable during transit — conditions that standard pharmaceutical cold-chain containers do not provide.

The company has deployed more than 400 Cellbox systems across three continents. Customers include cell therapy manufacturers, hospital research units, and contract research organisations that need to move live materials without the viability losses that standard cool-chain handling causes. The commercial model is rental-based: Cellbox provides the system per shipment or on a recurring subscription, building a recurring revenue stream and accumulating transit-condition data with each completed delivery.

A warm-chain infrastructure play

The financing positions Cellbox as infrastructure for the cell therapy expansion. CAR-T therapies and other autologous treatments depend on maintaining cell viability across a supply chain that spans hundreds or thousands of kilometres and multiple carriers. The controlled environment Cellbox provides is not a differentiating feature; it is a prerequisite for the shipment to work at all.

NRW.BANK and Fraunhofer Venture re-invested in the final close. NRW.BANK is the state development bank for North Rhine-Westphalia, a region that concentrates German pharmaceutical and biotech manufacturing. Fraunhofer Venture connects Cellbox to the 75-institute Fraunhofer network — the largest applied research organisation in Europe — for ongoing technical development. Baltic Business Angels Invest, bringing new capital to complete the round, adds a Baltic investor presence to the existing German institutional base.

The proceeds will be used to expand warm-chain logistics services across Europe, Asia, and North America and to scale the rental and recurring-service model.

Why it matters to investors

Cold-chain logistics — the refrigerated infrastructure that moves vaccines and drugs — is a solved problem at scale. Warm-chain logistics is not. Living biological materials — primary cells, tissue samples, cell therapy products under active CAR-T manufacturing — require not just temperature control but a full controlled atmosphere: the right CO₂ concentration, humidity, and gas exchange to keep cells viable across a transit that can take 12 to 48 hours. No standard pharmaceutical cold-chain container provides this. Cellbox built the hardware from the ground up and has now deployed more than 400 systems across three continents. The commercial model is the more interesting element: rather than selling containers, Cellbox rents them on a per-shipment or subscription basis. This means recurring revenue, a growing dataset of transit conditions, and the ability to tune the control algorithms with each completed delivery — a flywheel that becomes more defensible with each order. This is the final close of the Series A. The first tranche of €3.5M closed in March 2026; ProYarn did not cover it. The new close adds Baltic Business Angels Invest alongside existing backers NRW.BANK and Fraunhofer Venture. NRW.BANK is North Rhine-Westphalia's state development bank — institutional backing from a region that is home to Bayer, Lanxess, and a concentration of pharmaceutical and biotech manufacturers. Fraunhofer Venture is the investment arm of Europe's largest applied research organisation, which connects Cellbox to 75 institutes across Germany for technical collaboration. The 18-month risk is volume: the cell therapy market is growing but is still small relative to conventional pharmaceutical logistics, and each individual shipment is high-touch and complex to coordinate. The rental model requires building operational density — enough repeat customers in enough geographies that utilisation justifies the fleet and the per-shipment service margin.

Sources

Series A BioTech Germany Baltic Business Angels Invest NRW.BANK Fraunhofer Venture

Threaded to this story

BioTech · September 24, 2026

Every European round, in your inbox by 8am.

The day's seed and Series A rounds across France and Europe — threaded, sourced, and read in two minutes. Free.